Search

Your search keyword '"Takayuki Yoshimoto"' showing total 4 results
Start Over Author "Takayuki Yoshimoto" Journal oncoimmunology
4 results on '"Takayuki Yoshimoto"'

1. Protective effects against tumors and infection by interleukin-27 through promotion of expansion and differentiation of hematopoietic stem cells into myeloid progenitors

Author

Naoko Orii, Izuru Mizoguchi, Yukino Chiba, Hideaki Hasegawa, Mio Ohashi, Mingli Xu, Taro Nagai, Nakaba Ochiai, Yuki Mochizuki, Toshiyuki Owaki, and Takayuki Yoshimoto

Subjects
il-27, hematopoietic stem cells, myeloid progenitors, emergency myelopoiesis, antitumor activity, Immunologic diseases. Allergy, RC581-607, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Interleukin (IL)-27 is a multifunctional cytokine that belongs to the IL-6/IL-12 family and has potent antitumor activity through various mechanisms. Our novel findings indicate that IL-27 directly acts on hematopoietic stem cells and promotes their expansion and differentiation into myeloid progenitors to control infection and to eradicate tumors.

Published
2018
Full Text
View/download PDF

2. Protective effects against tumors and infection by interleukin-27 through promotion of expansion and differentiation of hematopoietic stem cells into myeloid progenitors

Author

Takayuki Yoshimoto, Yukino Chiba, Hideaki Hasegawa, Mio Ohashi, Taro Nagai, Mingli Xu, Nakaba Ochiai, Naoko Orii, Izuru Mizoguchi, Toshiyuki Owaki, and Yuki Mochizuki

Subjects
lcsh:Immunologic diseases. Allergy, 0301 basic medicine, Myeloid, medicine.medical_treatment, Immunology, Biology, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, medicine, Immunology and Allergy, antitumor activity, Interleukin 27, Progenitor cell, Author's View, Antitumor activity, il-27, Interleukin, emergency myelopoiesis, myeloid progenitors, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, hematopoietic stem cells, Haematopoiesis, 030104 developmental biology, Cytokine, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Cancer research, Stem cell, lcsh:RC581-607
Abstract

Interleukin (IL)-27 is a multifunctional cytokine that belongs to the IL-6/IL-12 family and has potent antitumor activity through various mechanisms. Our novel findings indicate that IL-27 directly acts on hematopoietic stem cells and promotes their expansion and differentiation into myeloid progenitors to control infection and to eradicate tumors.

Published
2018
Full Text
View/download PDF

3. Therapeutic potential of interleukin-27 against cancers in preclinical mouse models

Author

Mingli Xu, Yukino Chiba, Kaname Higuchi, Izuru Mizoguchi, Jun-ichi Furusawa, Ren Tsunoda, and Takayuki Yoshimoto

Subjects
Antitumor activity, Oncology, Immunology, TLR3, Immunology and Allergy, Interleukin 27, Biology, Pharmacology, Adverse effect, Author's View
Abstract

Since we first reported the antitumor efficacy of IL-27 in 2004, accumulating evidence obtained by several groups using a variety of preclinical mouse models indicates that IL-27 possesses potent antitumor activity against various types of tumors through multiple mechanisms depending on the characteristics of individual tumors without apparent adverse effects.

Published
2015
Full Text
View/download PDF

4. Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Author

Takayuki Yoshimoto, Junko H. Ohyashiki, Kazuma Ohyashiki, Junichiro Mizuguchi, Yukino Chiba, Tetsuzo Tauchi, Seiichiro Katagiri, Jun-ichi Furusawa, and Izuru Mizoguchi

Subjects
immunosurvelliance, Immunology, NK cells, Imatinib therapy, cytotoxic T lymphocytes, Text mining, chronic myeloid leukemia, hemic and lymphatic diseases, medicine, Immunology and Allergy, Cytotoxic T cell, Author's View, Predictive marker, business.industry, fungi, food and beverages, Myeloid leukemia, Imatinib, Immunosurveillance, imatinib, Oncology, Cancer research, business, predictive marker, Tyrosine kinase, medicine.drug
Abstract

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive markers to identify these patients who can stop imatinib without relapse.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results